Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease

Sean T. Campbell

doi:10.1093/clinchem/hvae038

Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease

Sean T. Campbell

Pathology

Research output: Contribution to journal › Short survey › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	1298
Number of pages	1
Journal	Clinical chemistry
Volume	70
Issue number	10
DOIs	https://doi.org/10.1093/clinchem/hvae038
State	Published - Oct 1 2024

ASJC Scopus subject areas

Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1093/clinchem/hvae038

Cite this

@article{4ef6c6bf8d7e428eba2043bd5b7d8d65,

title = "Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease",

author = "Campbell, \{Sean T.\}",

year = "2024",

month = oct,

day = "1",

doi = "10.1093/clinchem/hvae038",

language = "English (US)",

volume = "70",

pages = "1298",

journal = "Clinical chemistry",

issn = "0009-9147",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease

AU - Campbell, Sean T.

PY - 2024/10/1

Y1 - 2024/10/1

UR - https://www.scopus.com/pages/publications/85205528155

UR - https://www.scopus.com/pages/publications/85205528155#tab=citedBy

U2 - 10.1093/clinchem/hvae038

DO - 10.1093/clinchem/hvae038

M3 - Short survey

C2 - 39360998

AN - SCOPUS:85205528155

SN - 0009-9147

VL - 70

SP - 1298

JO - Clinical chemistry

JF - Clinical chemistry

IS - 10

ER -

Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this